| Compound | Description |
|---|
| arachidonic acid | An unsaturated, essential fatty acid. It is found in animal and human fat as well as in the liver, brain, and glandular organs, and is a constituent of animal phosphatides. It is formed by the synthesis from dietary linoleic acid and is a precursor in the biosynthesis of prostaglandins, thromboxanes, and leukotrienes. |
| leukotriene a4 | (2S-(2 alpha,3 beta(1E,3E,5Z,8Z)))-3-(1,3,5,8-Tetradecatetraenyl)oxiranebutanoic acid. An unstable allylic epoxide, formed from the immediate precursor 5-HPETE via the stereospecific removal of a proton at C-10 and dehydration. Its biological actions are determined primarily by its metabolites, i.e., LEUKOTRIENE B4 and cysteinyl-leukotrienes. Alternatively, leukotriene A4 is converted into LEUKOTRIENE C4 by glutathione-S-transferase or into 5,6-di-HETE by the epoxide-hydrolase. (From Dictionary of Prostaglandins and Related Compounds, 1990) |
| leukotriene b4 | The major metabolite in neutrophil polymorphonuclear leukocytes. It stimulates polymorphonuclear cell function (degranulation, formation of oxygen-centered free radicals, arachidonic acid release, and metabolism). (From Dictionary of Prostaglandins and Related Compounds, 1990) |
| leukotriene c4 | The conjugation product of LEUKOTRIENE A4 and glutathione. It is the major arachidonic acid metabolite in macrophages and human mast cells as well as in antigen-sensitized lung tissue. It stimulates mucus secretion in the lung, and produces contractions of nonvascular and some VASCULAR SMOOTH MUSCLE. (From Dictionary of Prostaglandins and Related Compounds, 1990) |
| 15-keto-5,8,11,13-eicosatetraenoic acid | RN given refers to (E,Z,Z,Z)-isomer; RN for cpd without isomeric designation not available 3/88 |
| 15-hydroxy-5,8,11,13-eicosatetraenoic acid | potent & selective inhibitor of platelet lipoxygenase; RN given refers to cpd without isomeric designation |
| 5,12,20-trihydroxy-6,8,10,14-eicosatetraenoic acid | RN given refers to (S-(R*,R*-(E,E,Z,Z)))-isomer |
| arachidonic acid 5-hydroperoxide | 5-HPETE is used inconsistently in literature as syn for cpds with various tetraene locants; RN given refers to (6,8,11,14)-isomer; RN in CA Vol 91 Form Index for (E,Z,Z,Z)-isomer: 70968-82-0; RN for (5,8,11,13)-isomer: 71133-12-5; in Merck, arachidonic acid is the (5,8,11,14)-isomer |
| 12-oxoleukotriene B4 | structure given in first source |
| 20-carboxyleukotriene b4 | metabolite of leukotriene B4 |
| leukotriene d4 | One of the biologically active principles of SRS-A. It is generated from LEUKOTRIENE C4 after partial hydrolysis of the peptide chain, i.e., cleavage of the gamma-glutamyl portion. Its biological actions include stimulation of vascular and nonvascular smooth muscle, and increases in vascular permeability. (From Dictionary of Prostaglandins and Related Compounds, 1990) |
| leukotriene e4 | A biologically active principle of SRS-A that is formed from LEUKOTRIENE D4 via a peptidase reaction that removes the glycine residue. The biological actions of LTE4 are similar to LTC4 and LTD4. (From Dictionary of Prostaglandins and Related Compounds, 1990) |
| arachidonic acid omega-9 hydroperoxide | |
| 15-hydroperoxy-5,8,11,13-eicosatetraenoic acid, (s)-(e,z,z,z)-isomer | |
| lipoxin a4 | an antifibrolytic agent; structure given in first source; a role in ASPIRIN antiinflammatory activity |
| lipoxin B4 | structure in first source |
| leukotriene C-2 | RN given refers to (R-(R*,S*-(E,E,E,Z)))-isomer |
| 12-hydroxy-5,8,10,14-eicosatetraenoic acid | A lipoxygenase metabolite of ARACHIDONIC ACID. It is a highly selective ligand used to label mu-opioid receptors in both membranes and tissue sections. The 12-S-HETE analog has been reported to augment tumor cell metastatic potential through activation of protein kinase C. (J Pharmacol Exp Ther 1995; 274(3):1545-51; J Natl Cancer Inst 1994; 86(15):1145-51) |
| 5-oxo-6,8,11,14-eicosatetraenoic acid | RN given is for cpd without isomeric designation; an arachidonate metabolite which stimulates neutrophils to mobilize Ca and promotes PMN degranulation responses |
| 12-keto-5,8,11,13-eicosatetraenoic acid | |
| 8,11,12-trihydroxy-5,9,14-eicosatrienoic acid | structure |
| trioxilin B3 | structure in first source |
| 20-aldehyde leukotriene B4 | |
| 5-hydroxy-6,8,11,14-eicosatetraenoic acid | |
| eoxin c4 | structure in first source |
| eoxin D4 | |
| eoxin E4 | |